206 related articles for article (PubMed ID: 26104056)
21. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
22. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.
Tripathi RKP; Ayyannan SR
Med Res Rev; 2019 Sep; 39(5):1603-1706. PubMed ID: 30604512
[TBL] [Abstract][Full Text] [Related]
23. Inhibition effects of Vernonia cinerea active compounds against cytochrome P450 2A6 and human monoamine oxidases, possible targets for reduction of tobacco dependence.
Prasopthum A; Pouyfung P; Sarapusit S; Srisook E; Rongnoparut P
Drug Metab Pharmacokinet; 2015 Apr; 30(2):174-81. PubMed ID: 25857233
[TBL] [Abstract][Full Text] [Related]
24. Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).
Riederer P; Jellinger K
Acta Neurol Scand Suppl; 1983; 95():43-55. PubMed ID: 6145282
[TBL] [Abstract][Full Text] [Related]
25. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Youdim MBH
J Neural Transm (Vienna); 2018 Nov; 125(11):1719-1733. PubMed ID: 30341696
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
Qhobosheane MA; Petzer A; Petzer JP; Legoabe LJ
Bioorg Med Chem; 2018 Nov; 26(20):5531-5537. PubMed ID: 30279044
[TBL] [Abstract][Full Text] [Related]
27. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
Dezsi L; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
[TBL] [Abstract][Full Text] [Related]
28. Clinical applications of MAO-inhibitors.
Riederer P; Lachenmayer L; Laux G
Curr Med Chem; 2004 Aug; 11(15):2033-43. PubMed ID: 15279566
[TBL] [Abstract][Full Text] [Related]
29. Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from
Lee HW; Kim YJ; Nam SJ; Kim H
J Microbiol Biotechnol; 2017 Feb; 27(2):316-320. PubMed ID: 27840401
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological and clinical implications of MAO-B inhibitors.
Yu PH
Gen Pharmacol; 1994 Dec; 25(8):1527-39. PubMed ID: 7721026
[TBL] [Abstract][Full Text] [Related]
31. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Bainbridge JL; Page RL; Ruscin JM
Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
[TBL] [Abstract][Full Text] [Related]
32. From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.
Deftereos SN; Dodou E; Andronis C; Persidis A
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):413-25. PubMed ID: 22943121
[TBL] [Abstract][Full Text] [Related]
33. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
[TBL] [Abstract][Full Text] [Related]
34. Plant secondary metabolites- potent inhibitors of monoamine oxidase isoforms.
Mathew B; Suresh J; Mathew GE; Parasuraman R; Abdulla N
Cent Nerv Syst Agents Med Chem; 2014; 14(1):28-33. PubMed ID: 25142815
[TBL] [Abstract][Full Text] [Related]
35. A Comprehensive Review of Monoamine Oxidase-A Inhibitors in their Syntheses and Potencies.
Rehuman NA; Mathew B; Jat RK; Nicolotti O; Kim H
Comb Chem High Throughput Screen; 2020; 23(9):898-914. PubMed ID: 32342809
[TBL] [Abstract][Full Text] [Related]
36. Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from
Chaurasiya ND; Zhao J; Pandey P; Doerksen RJ; Muhammad I; Tekwani BL
Molecules; 2019 Feb; 24(4):. PubMed ID: 30813423
[TBL] [Abstract][Full Text] [Related]
37. Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2012 Nov; 22(21):6632-5. PubMed ID: 23010267
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
[TBL] [Abstract][Full Text] [Related]
39. Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).
Carradori S; Petzer JP
Expert Opin Ther Pat; 2015 Jan; 25(1):91-110. PubMed ID: 25399762
[TBL] [Abstract][Full Text] [Related]
40. A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.
Kumar B; Gupta VP; Kumar V
Curr Drug Targets; 2017; 18(1):87-97. PubMed ID: 26648064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
